lower
respiratori
tract
infect
lrti
result
substanti
morbid
mortal
immunocompromis
children
approxim
children
undergo
hematopoiet
stem
cell
transplant
hsct
develop
lrti
improv
detect
pathogen
bal
specimen
critic
guid
antimicrobi
manag
direct
infect
prevent
control
strategi
understand
potenti
chang
epidemiolog
avoid
invas
diagnost
intervent
exampl
lung
biopsi
prior
studi
bal
perform
immunocompromis
children
report
detect
pathogen
mean
procedur
use
varieti
case
definit
patient
popul
howev
recent
studi
examin
diagnost
yield
bal
immunocompromis
pediatr
popul
compar
yield
differ
diagnost
assay
thu
primari
aim
studi
determin
overal
diagnost
yield
bal
immunocompromis
children
past
decad
compar
rate
isol
bacteri
fungal
viral
mycobacteri
pathogen
earli
versu
later
year
studi
period
hypothes
diagnost
yield
bal
perform
earlier
year
studi
would
lower
bal
perform
later
year
due
improv
diagnost
assay
secondari
aim
determin
bal
result
associ
chang
antimicrobi
therapi
retrospect
case
seri
immunocompromis
pediatr
patient
undergo
bal
perform
newyorkpresbyterian
morgan
stanley
children
hospit
columbia
univers
medic
center
new
york
new
york
decis
perform
bal
made
patient
primari
team
consult
pediatr
pulmonolog
servic
elig
subject
year
age
time
bal
multipl
underli
diagnos
tabl
identifi
case
bal
procedur
record
pediatr
pulmonolog
divis
review
subject
underw
one
bal
studi
period
procedur
includ
flexibl
bronchoscopi
perform
obtain
bal
specimen
patient
intub
endotrach
less
commonli
via
laryng
mask
airway
lma
site
bal
chosen
base
chest
imag
usual
ct
scan
find
time
bronchoscopi
bal
perform
multipl
site
multipl
area
involv
imag
bronchoscop
appear
institut
review
board
columbia
univers
medic
center
approv
conduct
studi
waiver
inform
consent
result
microbi
studi
perform
bal
review
includ
bacteri
cultur
fungal
cultur
afb
smear
cultur
viral
diagnost
studi
cultur
direct
fluoresc
assay
dfa
andor
enzymelink
immunoassay
eia
polymeras
chain
reaction
pcr
may
multiplex
revers
transcriptas
rt
pcr
assay
introduc
filmarray
biofir
diagnost
inc
salt
lake
citi
ut
compris
viral
bacteri
target
adenoviru
four
coronavirus
human
metapneumoviru
rhinovirusenteroviru
five
subtyp
influenza
ab
four
subtyp
parainfluenza
respiratori
syncyti
viru
bordetella
pertussi
chlamydophila
pneumonia
mycoplasma
pneumonia
result
cytolog
stain
pneumocysti
jiroveci
cyst
acidfast
organ
viral
inclus
evid
cytolog
transform
platelia
aspergillu
galactomannan
bal
biorad
hercul
ca
introduc
septemb
also
review
legionella
cultur
routin
sent
quantit
bal
introduc
institut
microbiolog
lab
end
studi
period
potenti
pathogen
defin
detect
pcr
growth
cultur
respiratori
virus
eg
rsv
parainfluenza
cytomegaloviru
cmv
herp
simplex
viru
hsv
nontubercul
mycobacteria
ntm
pathogen
bacteria
fungal
organ
eg
aspergillu
pneumocysti
mucor
spp
coagulaseneg
staphylococci
con
mix
commens
flora
consid
pathogen
studi
quantit
bal
perform
studi
pharmaci
record
electron
medic
record
emr
review
assess
whether
bal
result
associ
chang
antimicrobi
therapi
assess
chang
antimicrobi
therapi
record
treatment
initi
hr
prior
bal
day
follow
bal
patient
grew
mycobacteria
pharmaci
record
review
day
follow
bronchoscopi
intraven
inhal
antimicrobi
agent
adjunct
agent
exampl
cmvor
rsvspecif
immunoglobulin
collect
dose
antimicrobi
review
differenti
prophylact
treatment
regimen
emr
note
patient
primari
team
intens
care
team
review
determin
rational
chang
antimicrobi
therapi
antimicrobi
therapi
categor
target
nontarget
target
therapi
defin
antimicrobi
treat
identifi
bacteri
pathogen
base
suscept
result
nontarget
therapi
defin
antimicrobi
treat
identifi
pathogen
continu
neg
bal
antimicrobi
therapi
categor
follow
narrow
therapi
discontinu
nontarget
antimicrobi
discontinu
second
target
antimicrobi
ie
duplic
therapi
continu
target
therapi
continu
target
antimicrobi
calendar
day
chang
target
therapi
ad
target
antimicrobi
continu
calendar
day
continu
nontarget
therapi
continu
nontarget
antimicrobi
calendar
day
antimicrobi
therapi
record
treatment
could
reflect
categori
demograph
clinic
characterist
collect
emr
patient
underw
autolog
hsct
follow
plan
allogen
hsct
date
degre
myeloabl
first
hsct
use
analysi
radiograph
find
suggest
lrti
exampl
nonspecif
opac
nodul
ground
glass
opac
abstract
attend
radiologist
electron
report
comput
tomographi
ct
perform
within
day
bal
avail
chest
radiograph
recent
ct
perform
radiograph
find
report
subject
ie
scar
mass
reticul
increas
attenu
exclud
analysi
studi
power
detect
associ
find
potenti
pathogen
analyz
potenti
factor
associ
isol
pathogen
bal
assess
binari
variabl
sex
transplant
statu
use
chisquar
fisher
exact
test
student
ttest
applic
factor
associ
posit
bal
find
bivari
analysi
pvalu
assess
multilogist
regress
pvalu
consid
signific
proport
specimen
sent
test
year
versu
well
overal
yield
bal
perform
period
compar
via
test
proport
type
microorgan
bacteri
fungal
ntm
andor
virus
detect
two
time
interv
similarli
analyz
addit
yield
first
versu
second
bal
perform
within
day
first
bal
compar
subject
bal
perform
radiograph
find
associ
isol
potenti
pathogen
compar
via
fisher
exact
test
statist
analysi
perform
use
sa
version
cari
nc
studi
period
subject
mean
age
year
rang
year
underw
bal
demograph
clinic
characterist
subject
includ
underli
diagnos
shown
tabl
major
subject
n
undergon
hsct
prior
bal
mean
time
first
hsct
bal
day
rang
day
factor
includ
hsct
transplant
statu
degre
myeloabl
predict
detect
potenti
pathogen
thirtyon
subject
bal
perform
among
second
bal
within
year
first
mean
time
second
bal
day
rang
day
overal
bal
yield
microorgan
fig
tabl
addit
type
microorgan
detect
earlier
versu
later
era
similar
overal
commonli
isol
organ
gramneg
bacilli
gnb
cmv
candida
speci
cultur
anaerob
pathogen
n
legionella
n
actinomyc
n
nocardia
n
mycoplasma
n
neg
signific
increas
obtain
fungal
cmv
cultur
year
compar
earlier
year
studi
p
addit
later
year
studi
decreas
viral
cultur
p
increas
viral
comprehens
panel
p
former
supplant
latter
institut
proport
bal
sent
bacteri
cultur
afb
cultur
cytolog
examin
similar
time
twelv
subject
second
bal
perform
within
day
first
bal
yield
first
bal
diagnost
yield
second
bal
three
second
bal
detect
new
microorgan
includ
candida
krusei
aspergillu
niger
pseudomona
aeruginosa
major
bal
preced
abnorm
find
ct
scan
n
chest
radiographi
nonspecif
opac
n
nodul
n
ground
glass
opac
n
significantli
associ
detect
potenti
pathogen
tabl
major
studi
subject
subject
receiv
antimicrobi
agent
time
bal
receiv
one
agent
respect
mean
durat
antimicrobi
therapi
prior
bal
day
rang
day
therapi
narrow
ie
least
one
nontarget
agent
discontinu
follow
neg
bal
howev
nontarget
agent
also
continu
follow
neg
bal
follow
posit
bal
therapi
continu
chang
target
therapi
posit
bal
result
continu
target
therapi
bacteri
fungal
organ
identifi
posit
bal
result
chang
target
therapi
viral
mycobacteri
organ
identifi
studi
describ
larg
cohort
immunocompromis
children
underw
bal
period
found
infecti
diagnost
yield
bal
identifi
demograph
clinic
risk
factor
associ
detect
potenti
pathogen
subject
undergon
hsct
andor
receiv
myeloabl
condit
regimen
like
detect
pathogen
howev
radiograph
find
nonspecif
opac
ground
glass
opac
nodul
like
associ
isol
potenti
pathogen
presenc
find
may
therefor
clinic
util
decis
perform
bal
immunocompromis
children
rate
posit
bal
previou
studi
rang
shown
tabl
variabl
like
reflect
institut
differ
patient
popul
bal
test
modal
local
epidemiolog
pathogen
perhap
importantli
case
definit
pathogen
microorgan
vari
contrast
current
studi
studi
includ
con
mix
commens
flora
pathogen
yet
other
various
exclud
isol
cmv
candida
spp
ntm
aspergillu
spp
airway
contamin
contrari
hypothesi
rate
isol
potenti
pathogen
higher
earlier
year
studi
later
year
although
statist
signific
despit
fact
significantli
sampl
submit
fungal
cmv
cultur
later
studi
period
result
indic
major
patient
multipl
antimicrobi
time
bal
may
affect
cultur
result
addit
last
two
decad
isol
viral
microorgan
bal
decreas
overal
may
reflect
improv
antivir
prophylaxi
patient
cmvseroposit
decreas
incid
pneumocysti
pneumonia
due
prophylaxi
organ
also
well
document
furthermor
neg
bal
may
reflect
noninfecti
caus
lower
tract
diseas
graftversushost
diseas
pulmonari
fibrosi
previous
describ
recent
comparison
studi
suggest
lung
biopsi
may
elucid
noninfecti
diagnos
manner
superior
bal
though
procedur
associ
higher
morbid
mortal
bal
studi
support
observ
made
prior
seri
posit
result
bal
impact
treatment
decis
found
neg
bal
associ
discontinu
least
one
nontarget
antimicrobi
although
often
anoth
nontarget
agent
continu
addit
major
posit
bal
associ
chang
target
antimicrobi
viral
mycobacteri
pathogen
thu
prescrib
improv
follow
bal
singl
center
retrospect
studi
limit
diagnost
test
perform
everi
bal
unabl
consist
determin
reason
also
examin
whether
indic
bronchoscopi
eg
fever
worsen
respiratori
statu
radiograph
find
associ
detect
potenti
pathogen
furthermor
could
assess
use
rtpcr
respiratori
viral
pathogen
institut
introduc
technolog
may
could
assess
use
aspergillu
galactomannan
test
sent
furthermor
quantit
bal
analysi
unavail
studi
period
studi
suffici
power
detect
associ
relaps
refractori
diseas
type
chemotherapi
differ
condit
regimen
yield
bal
analyz
associ
neutropenia
yield
bal
radiograph
find
final
could
conclus
determin
provid
rational
continu
nontarget
therapi
discontinu
target
therapi
bal
contribut
treatment
decisionmak
immunocompromis
patient
presum
lrti
continu
role
care
popul
multicent
studi
perform
valid
case
definit
posit
bal
examin
rel
contribut
newer
diagnost
modal
assess
impact
bal
antimicrobi
manag
author
wish
acknowledg
philip
zachariah
md
divis
pediatr
infecti
diseas
assist
statist
analysi
also
wish
thank
